Rivaroxaban with aspirin
Prevention of cardiac events in patients with coronary (CAD) or peripheral artery Disease (PAD) (NICE TA607)
Rivaroxaban plus aspirin is recommended within its marketing authorisation, as an option for preventing atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease who are at high risk of ischaemic events.
Reason for decision:
Suitable for initiation in primary care